Cetera Investment Advisers
ADPT icon

Cetera Investment Advisers’s Adaptive Biotechnologies ADPT Stock Holding History

Cetera Investment Advisers’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$397K Sell
18,493
-23,914
-56% -$366K ﹤0.01% 3906
2026
Q1 		$589K Buy
42,407
+12,221
+40% +$195K ﹤0.01% 3357
2025
Q4 		$490K Buy
30,186
+18,491
+158% +$302K ﹤0.01% 3455
2025
Q3 		$175K Buy
+11,695
New +$143K ﹤0.01% 4188

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Cetera Investment Advisers's ADPT Position: Q2 2026 in Review

Cetera Investment Advisers reduced its Adaptive Biotechnologies (ADPT) stake by 56% in Q2 2026, selling an estimated $366K and leaving 18,493 shares worth $397K. The position accounts for ﹤0.01% of the portfolio, ranked #3906.

Cetera Investment Advisers first reported a position in ADPT in Q3 2025 and has held it in 4 quarters since. The position peaked at $589K in Q1 2026. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Cetera Investment Advisers held 18,493 shares of Adaptive Biotechnologies worth $397K as of Q2 2026.
  • Cetera Investment Advisers sold 23,914 Adaptive Biotechnologies shares in Q2 2026, an estimated $366K.
  • Adaptive Biotechnologies made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #3906 holding.
  • Cetera Investment Advisers first reported a position in Adaptive Biotechnologies in Q3 2025 and has held it in 4 quarters since.
  • Cetera Investment Advisers's Adaptive Biotechnologies position peaked at $589K in Q1 2026.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.